Q-omics provides the consensus-scored LRRC31 profile across patient tissues and cancer cell-line models. LRRC31 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, LRRC31 is differentially expressed in 14, with the highest sampling consensus in COAD. Additionally, LRRC31 RNA expression shows 15,422 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight KIRC, COAD, and LUAD as cancer lineages where LRRC31 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LRRC31 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LRRC31 survival associations across molecular data types. LRRC31 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (7) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LRRC31 RNA expression–survival associations across cancer types. High LRRC31 expression shows unfavorable associations in DLBC, but favorable associations in KIRC, HNSC, SKCM, UVM and KIRP. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for LRRC31 RNA expression.
This table summarizes LRRC31 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for LRRC31. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LRRC31 shows lower tumor expression in COAD, LUSC, HNSC and READ and higher tumor expression in BRCA and KICH. The COAD box plot shows higher LRRC31 RNA expression in normal versus tumor tissue (log2 FC = −1.550, t-test p < 0.001).
This table shows molecular features associated with LRRC31 in patient tissues and cancer cell lines. In patient samples, LRRC31 shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set. In cancer cell lines, LRRC31 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and SKIN.
